Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial
Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers.
Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial Read More »
